Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Amplitude Healthcare Acquisition — SPAC Merger (June 2021)
36 slides from Jasper Therapeutics's SPAC merger presentation, Jun 8, 2021
Slide 1: JSP191 Overview and Phase 1 MDS/AML 90-day Data Presented at 2021 ASCO
oy Jasper THERAPEUTICS INC. JSP191 Overview and Phase 1 MDS/AML 90-day Data Presented at 2021 ASCO Annual Meeting
Slide 2: Safe Harbor Statement
Safe Harbor Statement (Jasper Se Seca ech ene ecm es a eco a ee a a re re Na Pi a a a poatosss SRT wn enemies ian en as a tert rt sy eet oi cece at en eco ena caste pa ee oe ean scene an pon an see oes ane payee eae ha falc ee ‘sSetcge oncomime seit nts mn npn sey orpann senses pe ay sR CxS oe han a
Slide 3: Leading in Hematopoietic Stem Cell Transplant Therapies
Leading in Hematopoietic Stem Cell Transplant Therapies Ojvasper Engineered HE. Stem Cells Focused on the Stem Cell & Stem Cell Biology SP191 is an investigative drug and is not approves
Slide 4: Agenda and Speakers
Agenda and Speakers Jasper ened = Kevin N. Heller, M.D. ‘Wendy Pang, M.D., Ph.D. Lori Muffly, M.D., M.S. Gail J. Roboz, M.D. Executive Vice President, Vice President, Assistant Professor of Medicine Professor of Medicine Research & Development, Research & Translational Medicine, (Blood and Bone Marr
Slide 5: Jasper and JSP191 Overview
6) Jasper THERAPEUTICS INC Jasper and JSP191 Overview Kevin N. Heller, M.D. Executive Vice President, Research & Development OO
Slide 6: Unmet Medical Need: Hematopoietic Stem Cell Transplants (HSCT)
Unmet Medical Need: Hematopoietic Stem Cell Transplants (HSCT) a) Jasper Most Powerful Form of Disease Cure, Yet Remain Underutilized —=- Limitations of Conditioning (prepare patient's bone marrow) + Old SOC agents are genotoxic Zo + Major Toxicities and AEs: Jasper Therapeutics > Veno-seeuaive Deaa
Slide 7: HSCT is Limited by Treatment Related Toxicity of Current Conditioning
HSCT is Limited by Treatment Related Toxicity of Current Conditioning jYasper Current MDS/AML Conditioni Myeloablative | Reduced Intensity Flu/TBI (MAC) (RIC) Veno-Occlusive Disease by Day 100 11.9%! 5.7%! 0.0%? Acute GvHD Grade 2-4 by Day 100 44.7%? 31.6%? 26.0% 2 2 7.7% Oral Mucositis Grade 3-4 by
Slide 8: Jasper's JSP191 Anti-CD117 Antibody Targets Stem Cell Factor Receptor
Jasper’s JSP191 Anti-CD117 Antibody Targets Stem Cell Factor {) Jasper Receptor to Address Limitations of Conditioning Taerareaies JSP191 Blocks SCF 1 Donor or Gene-Corrected Binding to CD117 Say Iba HSC Home to BM Niche RRO ES SOF . ° NS d Z _ ¥ wR Xt nn nA JSP191 Stroma Cells. Stroma Cells Stroma
Slide 9: Jasper Engineered Hematopoietic Stem Cells (eHSC) Platform
Jasper Engineered Hematopoietic Stem Cells (eHSC) Platform: a) Jasper Unlocking the Potential of Stem Cells oes © Fatont stem cols @ Unmodied donor stem cals @ Encincered stem cells Jasper eHSCs Replete / Modified Grafts mRNA Engineering Non-engineered Transplant: UNMODIFIED DONOR STEM CELLS ENGINEE
Slide 10: Jasper's Expanding Pipeline
Jasper’s Expanding Pipeline (j Jasper INDICATION RESEARCH PRECLINICAL CLINICAL R&D PARTNER: JSP191 CONDITIONING (Lupus, MS, Scleroderma) Sickle Cell Disease Chronic Granulomatous Disease Gene Therapy (X-SCID) 3 GRAPHITE BIO Jasper eHSC PLATFORM ‘Thalassemias Sickle Cell Disease Autoimmune Diseases J
Slide 11: JSP191 Mechanism of Action & Preclinical Data
6) Jasper THERAPEUTICS INC JSP191 Mechanism of Action & Preclinical Data Wendy Pang, M.D., Ph.D. Vice President, Research & Translational Medicine ©2021 Jasper Ther Inc.
Slide 12: JSP191 Anti-CD117 Antibody to Address Conditioning Limitations
JSP191 Anti-CD117 Antibody to Address Conditioning Limitations Stem Cell Factor (SCF) Binds to CD117 JSP191 Blocks SCF Binding to CD117 ‘SCF JSP191 SCF / CD117 interaction required for stem cell survival Inhibition of Stem Cell Survival Signal leads to stem cell depletion in bone marrow [1] Bankova
Slide 13: JSP191 as a Single Agent Causes Robust And Transient Depletion Of Hematopoietic Stem Cells
JSP191 as a Single Agent Causes Robust And Transient Depletion Of {) Jasper Hematopoietic Stem Cells in Non-Human Primates and Patients oes 6 blo od Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primates and humanized NSG mice Hye:Sook Kwon, Aaron C. Logan, Akanksha Chh
Slide 14: JSP191 Targets and Depletes Disease Initiating Stem Cells in MDS/AML
JSP191 Targets and Depletes Disease Initiating Stem Cells in MDS/AML Oj vasper Depletes MDS stem cells © 2021 Jasper Therapeuti blood Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenogratted mice ‘Wendy W. Pang, Agnieszka Czechowicz, Aaron ©. Log
Slide 15: Anti-CD117 Ab Unique MOA: Synergy With Low Dose Radiation
Anti-CD117 Ab Unique MOA: Synergy With Low Dose Radiation To tjJa er Allow Engraftment Equivalent to High Dose Radiation ee Anti-CD117 + _ Low Dose Radiation Radiation only 100 7 rH 100: £ a + £8 % Be @ i s 60: © 32 « 3£ ER 5% jie ag » CY A § ° 2000Gy 200 Gy 250cGy 450cGy 700cGy CD17 Chhabra et al.
Slide 16: JSP191 Single Agent Activity and Safety in SAD/MAD and SCID Patients
JSP191 Single Agent Activity and Safety in SAD/MAD and SCID fj Jasper Patients eee ‘SCID is a lethal genetic immune disorder. HCT is the only proven cure, without it most infants die before the age of two years. Phase 1 SAD/MAD (n = 77) in healthy volunteers ical Trial Jasper SCID C Single Arm Trial
Slide 17: JSP191 ASCO Data
0) Jasper THERAPEUTICS INC JSP191 ASCO Data Lori Muffly, M.D., M.S. Assistant Professor of Medicine (Blood and Bone Marrow Transplantation), Stanford Medicine ©2021 vk
Slide 18: JSP191 Updated 90-day Data from Phase 1 MDS/AML Clinical Trial
JSP191 Updated 90-day Data from Phase 1 MDS/AML Clinical Trial Early Results of Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, with Non-Myeloablative Conditioning in Older Adults with MRD- positive MDS/AML Undergoing Allogenic Hematopoietic Cell Transplantation Authors: Lori S. Mutly',
Slide 19: JSP191 Open-label, Multicenter Phase 1 Study Design
JSP191 Open-label, Multicenter Phase 1 Study Design Inclusion Criteria + Patients age 65 to 74 years with MDS or AML undergoing hematopoietic cell transplantation + Patients were ineligible for full myeloablative conditioning Study Endpoints + Primary: safety and tolerability of JSP191 as a conditio
Slide 20: JSP191 Pharmacokinetics and Safety
JSP191 Pharmacokinetics and Safety Cj Jasper JSP191 PK at 0.6 mg/kg was observed to be consistent among subjects (n = 6) 116000 JSP191 when added to TBI/Flu appears to be safe and tolerable + No infusion reactions ‘a0 . + No treatment related toxicities E 00 y + Protocol allows for outpatient condit
Slide 21: Neutropenia Followed by Donor Cell Engraftment Suggests Successful Myeloablation
Neutropenia Followed by Donor Cell Engraftment Suggests Successful ) Jasper Myeloablation Using JSP191/TBI/Flu Combination ~ a ‘lal Blood Chimeren 8 Myeloid mera Absolute Neutrophil Count (ANC) 7 om Ane (wk) 20 “Time Relative to Transplant Day 0 20008 -e-coot -e-o005 ~e-c008 —e-c010 —e-o011 + Subjec
Slide 22: JSP191 Conditioning Leads to Successful Transplant and Conversion to MRD-Negative
JSP191 Conditioning Leads to Successful Transplant and Conversion to fj Jasper MRD-Negative/ MRD Reduction in First Five Evaluable Subjects — Subject Screening T0128 TD+56 10490 Number NGS, Flow, orCyto NGS, Flow, or Cyto NGS, Flow,or Cyto NGS, Flow, or Cyto NGS, Flow, or Cyto IDNMT3A (VAF: 4.7%) |D
Slide 23: Key Takeaways
Key Takeaways (jJasper JSP191 0.6 mg/kg added to low dose radiation (2Gy) and fludarabine was well 2021 ASCO tolerated in all six patients and led to successful transplant as evidenced by . : ANNUAL MEETING + Full chimerism (greater than 95%) in five of six patients by Day 90 * Elimination of MRD in
Slide 24: JSP191 Clinical Perspective
*y Jasper WA Tiemavcurics ne JSP191 Clinical Perspective Gail J. Roboz, M.D. Professor of Medicine (Hematology & Medical Oncology) and Director of the Clinical and Translational Leukemia Program, Weill Cornell Medicine
Slide 25: Background: Unmet Medical Need
Background: Unmet Medical Need (Jasper 2017 ELN AML Classification: Survival of Patients > 60 Yrs of Age by Risk Group 10 Disease-Free Survival 1.0 os 08 08 3 § 6 0.6 P<.001 £06 P<,.001 2 3 a 04 04 5 ELN Favorable (n = 99) 8 ELN Favorable (n = 121) ELN Intermediate (n = 54) ELN Intermediate (n = 101
Slide 26: Background: Unmet Medical Need
Background: Unmet Medical Need Increasing use of allogeneic hematopoi © 2021 Jasper Ther cell transplantation years and older in the United States (Jasper patients aged 70 Absolute number of transplants o8S8S8R5R = AML N oe 3 7 o 7 3 2 5 3 4 MDSIMPS -® Non-Hodgkin lymphoma -* Others 16 13 15 34 92 5
Slide 27: Background: Unmet Medical Need
Background: Unmet Medical Need (Jasper Allogeneic transplantation has high 2-year non-relapse mortality in patients > 60 years Table 1. Estimated two-year NAM in original and age-incorporating HCT-Cl score. The original HCT-CI score is regardless of age, the estimated NRM by the HCT-Ci/age score sho
Slide 28: Background:
Background: 100 = 80 2 5 60 Significant decrease 8 in survival probability a for NGS positive/RIC = 40 ro B g 20 NESPoHEMET) ac Re 2002 0 0 1 2 3 Years Data presented in the Presidential Symposium at EHA Annual Congress 2019 by Hourigan et al. (© 2021 Jasper Therapeutics, Inc. ISP191 Is an investiga
Slide 29: Background: QUAZAR AML-001 Overall Survival
Background: QUAZAR AML-001 Overall Survival Jasper Stratified P value: 0.0009 80-486 (n= 258) Stratified HR: 0.69 [95%CI 0.55, 0.86] ~----Placebo (n = 234) 4.9.9 months 24.7 months © [95%C! 18.7, 30.5] Median follow-up: 41.2 months 14.8 months [95%C! 11.7, 17.8) 00 0 é 12 18 24 30 36 2 48 54 60 66 n
Slide 30: Background: VIALE-A (Venetoclax + Aza vs Aza) Overall Survival
Background: VIALE-A (Venetoclax + Aza vs Aza) Overall Survival (Jasper 10 Median OS, mos (95% Cl) 5 a — Aza+Ven 14.7 (11.9 - 18.7) 3 — Aza+Pbo 9.6 (7.4 - 12.7) 2 5 06 HR: 0.66 (95% Cl: 0.52-0.85), P< .001 > B04 Median follow-up: 3 20.5 months £ 02 0.0 No. at Risk Mos Aza+Ven 286 219 198 168 143 117
Slide 31: Background: Allogenic Transplant improves outcomes compared to maintenance Aza/Venetoclax
Background: Allogenic Transplant improves outcomes compared to ; (Jasper maintenance Aza/Venetoclax : Table 1: Disease Status Characteristics 21 patients, median age 65 (60-73) ELN Rsk High Intermediate 3 4 Figure 1: Overall survival Favorable 3 40 | Disease stats atscTconsut [| — HSCT CRICRI withou
Slide 32: Questions & Answers
0) Jasper THERAPEUTICS INC Questions & Answers
Slide 33: Risk Factors
Risk Factors Jasper “The lit below of ik ators has been prepared solely for purposes of the proposed pate placement transaction (the “Private Placement”) a8 part of he proposed busines combination the “Business Combination") of _Amplitude Healthcare Acquistion Corp. ("AMC") and Jasper Therapeutics,
Slide 34: Risk Factors (cont'd)
Risk Factors (cont'd) Jasper sks Rated to the Regulatory Regime for Jaspers Product Candidates Jasper has no experience asa company in obtaining regulatory approval for» drug. ‘The regulator landscape that wll gover Jasper’ product candidates i uncetan; regulations eating to more established celular
Slide 35: Risk Factors (cont'd)
Risk Factors (cont'd) Jasper sks Rated to aspers Intellectual Property Jaspers commercial success depends ons ait to obtain, maintain and protects intellectual property and proprietary technology ‘The patent protection Jasper obtains forts product candidtes may not be sufien enough to provide it wit
Slide 36: Risk Factors (cont'd)
Risk Factors (cont'd) Jasper sks Related to the Private Placement [ANNHC may be unable to raise suicientcapitlin the Private Placement or otherwise obtain addtional nancng to complete the Business Combination orto fund the operations and growth ofthe combined company folowing ‘the Business Combinati
Amplitude Healthcare Acquisition — SPAC Merger (June 2021) on 6ix